NCT06533670Active, not recruitingNot Applicable
Tumor Microenvironment Alteration During Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer Patients
Seoul National University Hospital1 site in 1 country30 target enrollmentStarted: July 19, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- tumor microenvironment alteration
Study Overview
Brief Summary
Evaluate for changes in the tumor microenvironment before/during neoadjuvant chemotherapy and after treatment in patients diagnosed with HER2-positive advanced breast cancer and receiving neoadjuvant cancer therapy and surgery for curative purposes.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •i. Adult patients over 18 years of age ii. Patients undergoing curative treatment including neoadjuvant chemotherapy after confirmation of breast cancer without distant metastases iii. Clinical T stage II-IV patients iv. HER2 positive breast cancer patients
Exclusion Criteria
- •If you have other comorbidities that, according to the researcher's judgment, may affect the results of the study
Outcomes
Primary Outcomes
tumor microenvironment alteration
Time Frame: 6 months
tumor microenvironment changes during neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer.
Secondary Outcomes
No secondary outcomes reported
Investigators
Wonshik Han
Professor
Seoul National University Hospital
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast CancerTriple Negative Breast CancerNeoadjuvant ChemotherapyPembrolizumabTumor MicroenvironmentNCT05910710Samsung Medical Center50
Recruiting
Not Applicable
Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer Using Ultrafast DCE-MRIBreast CancerNCT05744518Fudan University80
Completed
Phase 2
Phase II Trial for Large ER-Negative Breast CancersMalignant Neoplasm of Female BreastNCT01869192University of Colorado, Denver72
Active, not recruiting
Not Applicable
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast CancerInvasive Breast CarcinomaNCT04897009Mayo Clinic38
Completed
Phase 2
Chemotherapy followed by radiotherapy response assessment in muscle invasive urinary bladder carcinomaCTRI/2017/08/009318ONE20